Pfizer und BioNTech veröffentlichen Daten zu starker Immunantwort nach Auffrischungsimpfung mit dem COVID-19-Impfstoff bei Kindern im Alter von 5 bis 11 Jahren
14 avr. 2022 06h45 HE
|
BioNTech SE
Daten einer Subanalyse mit 30 Seren aus einer klinischen Phase-2/3-Studie mit Kindern im Alter von 5 bis 11 Jahren zeigen einen 36-fachen Anstieg der neutralisierenden Antikörpertiter gegen die...
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
14 avr. 2022 06h45 HE
|
BioNTech SE
Data from a subanalysis of 30 sera from a Phase 2/3 clinical trial of children 5 through 11 years of age show a 36-fold increase in SARS-CoV-2 Omicron neutralizing titers following a booster (third)...
Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic’s Licensed C1 Protein Production Platform
13 avr. 2022 08h52 HE
|
Dyadic International, Inc.
India’s Department of Biotechnology, Government of India to support scale up and production of cGMP batches of SARS-CoV-2 antigenFunding earmarked to support Phase 1 and 2 clinical trials of Epygen’s...
FXCM February Single Share & Stock Baskets Report
28 mars 2022 04h00 HE
|
FXCM Group
LONDON, March 28, 2022 (GLOBE NEWSWIRE) -- FXCM Group, LLC (“FXCM Group’ or ‘FXCM’), the leading international provider of online foreign exchange trading, CFD trading, cryptocurrencies and related...
FXCM February Single Share & Stock Baskets Report
28 mars 2022 04h00 HE
|
FXCM Group
SYDNEY, Australia, March 28, 2022 (GLOBE NEWSWIRE) -- FXCM Group, LLC (“FXCM Group’ or ‘FXCM’), the leading international provider of online foreign exchange trading, CFD trading, cryptocurrencies...
FXCM February Single Share & Stock Baskets Report
24 mars 2022 10h07 HE
|
FXCM Group
JOHANNESBURG, South Africa, March 24, 2022 (GLOBE NEWSWIRE) -- FXCM Group, LLC (“FXCM Group’ or ‘FXCM’), the leading international provider of online foreign exchange trading, CFD trading,...
Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults
15 mars 2022 18h00 HE
|
BioNTech SE
Submission based on real-world safety and efficacy data from Israel Data showed rates of confirmed infections were 2 times lower and rates of severe illness were 4 times lower among individuals who...
Xanadu Bio Obtains Licenses and Options to Novel Platform Technologies from Yale University to Develop an Intranasal SARS CoV-2 mRNA Vaccine Booster Aimed at Inducing Local Mucosal Immunity to Prevent SARS CoV-2 Infection and Virus Transmission
08 févr. 2022 07h30 HE
|
Xanadu Bio
~ Company licenses PACE, a next generation polymeric nanoparticle delivery platform, and options intranasal PACE/Spike mRNA and Spike recombinant protein vaccine boosters for the treatment of...
Pfizer und BioNTech beginnen rollierenden Einreichungsprozess für Notfallzulassung ihres COVID-19 Impfstoffs bei Kindern im Alter von 6 Monaten bis 4 Jahren auf Anfrage der U.S.-amerikanischen FDA
01 févr. 2022 16h27 HE
|
BioNTech SE
Da die Zahl der pädiatrischen COVID-19 Fälle die 10 Millionen-Grenze überschritten hat und aufgrund einer Anfrage der U.S.-amerikanischen Zulassungsbehörde FDA, haben die Unternehmen die verfügbaren...
Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request from U.S. FDA
01 févr. 2022 16h27 HE
|
BioNTech SE
With pediatric COVID-19 cases surpassing 10 million and at the request of the FDA, the companies have submitted available data on the safety and efficacy of two 3 µg doses as part of a three-dose...